Efficacy outcomes according to eGFR category in patients treated with tenecteplase
| eGFR (mL/min/1.73 m2) | Event rate (%) | Crude effect size (95% CI) | P value | Adjusted effect size (95% CI)* | P value | |
| Primary outcome | ||||||
| mRS score 0–1 at 90 days | ≥90 | 302 (65.5) | 1 | 1 | ||
| 60–89 | 114 (58.8) | 0.75 (0.53 to 1.06) | 0.10 | 0.92 (0.61 to 1.39) | 0.68 | |
| ＜60 | 21 (46.7) | 0.46 (0.25 to 0.85) | 0.01 | 0.60 (0.30 to 1.25) | 0.17 | |
| Secondary outcome | ||||||
| mRS score 0–2 at 90 days | ≥90 | 355 (77.0) | 1 | 1 | ||
| 60–89 | 132 (68.0) | 0.64 (0.44 to 0.92) | 0.02 | 0.78 (0.50 to 1.23) | 0.29 | |
| ＜60 | 26 (57.8) | 0.41 (0.22 to 0.77) | 0.01 | 0.58 (0.27 to 1.27) | 0.18 | |
| European Health-Related Quality of Life at 90 days | ≥90 | 80 (70 to 91) | 1 | 1 | ||
| 60–89 | 80 (60 to 95) | −0.61 (−4.16 to 2.93) | 0.73 | 0.74 (−2.81 to 4.30) | 0.68 | |
| ＜60 | 80 (55 to 90) | −6.33 (−13.28 to 0.62) | 0.07 | −3.94 (−10.63 to 2.75) | 0.25 | |
| Barthel index score≥95 at 90 days | ≥90 | 325 (73.0) | 1 | 1 | ||
| 60–89 | 114 (65.2) | 0.70 (0.48 to 1.02) | 0.06 | 1.14 (0.73 to 1.78) | 0.56 | |
| ＜60 | 21 (60.0) | 0.55 (0.27 to 1.12) | 0.10 | 1.23 (0.53 to 2.81) | 0.63 | |
Data are expressed as n/N (%), effect size (95% CI), median (IQR) or p value.
Scores on the mRS range from 0 to 6, with 0 indicating no disability, 3 indicating moderate disability and 6 indicating death.
The association between eGFR as a categorical variable and the efficacy and safety outcome was estimated by calculating the ORs with 95% CIs using binary logistic regression models. β-coefficient with its 95% CI was calculated using general linear model for the outcome of European quality of life visual analogue scale.
*The models were adjusted for age, sex, baseline National Institutes of Health Stroke Scale, history of hypertension, history of antiplatelet and anticoagulant drug use, onset-to-needle time and bridging thrombectomy.
eGFR, estimated glomerular filtration rate; mRS, modified Rankin Scale.